Adverse effects of treatment with intravenous immunoglobulins for neurological diseases
β Scribed by Matthias Wittstock; Uwe K. Zettl
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 185 KB
- Volume
- 253
- Category
- Article
- ISSN
- 0340-5354
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effect of intravenous immunoglobulin (IVIG) on various laboratory values was measured immediately before and after completion of serial monthly infusions of IVIG (2 g/kg) or an equal volume of placebo over 3-12 months, in 46 patients with neuromuscular diseases participating in controlled trials
The therapeutic effects of intravenous immunoglobulin (IVIG) on the stiff-person syndrome (SPS) have been described exclusively in case reports or open-label studies in terms of clinical outcomes. We investigate whether IVIG improves quality of life (QoL) in the SPS. Six patients with the classic fo
Treatment with high-dose (400 mg/kg/ day) intravenous immunoglobulin ( M g ) shows benefit in many autoimmune diseases but is very expensive. Low-dose M g has also been shown to be effective in inhibiting adjuvant arthritis in the rat. This pilot, randomized, double-blind, placebo-controlled trial w
Infection with the human immunodeficiency virus (HIV) frequently is complicated with thrombocytopenia (HIV-Thr) during all stages of the infection. The treatments for autoimmune thrombocytopenic purpura (ITP) are used in HIV-Thr; however, their effects upon the immune status of patients with acquire